Market Size (2018)
2018
$10.80B
Healthcare
Dercum’s Disease Market
By Segment, By Region, And Segment Forecasts, 2018 – 2030
Vertical: HealthcareBase Year: 202112 Sections
Executive Summary
Dercum’s Disease Market — Snapshot
Projected (2030)
2030
$19.96B
CAGR (2018–2030)
5.2%
5.2%Key Players
108+
Dercum’s disease is a rare disorder described by multiple, painful growths of fatty tissue (lipomas). The key factors attributing to driving the market growth are the rising prevalence of rare diseases. However, the lack of awareness among people about the disease is a threat to the growth of the market. In contrast, a rising number of strategic initiatives is likely to create market opportunities for global market leaders.
Key Insight
The Dercum’s Disease Market market is projected to grow at a CAGR of 5.2% from 2018 to 2030.
Market Performance Trend
Historical performance and future projections (2020–2030, USD Billion)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Scope & Coverage
What this report covers
- Geographic Coverage: This analysis covers 4 regions: North America, Europe, Asia Pacific, Rest of the World.
- Market Segmentation: The market is analyzed across 6 segments: Surgery, Liposuction, Medication, Electrotherapy, Acupuncture, Others. Forecasts are provided for each segment from 2018 to 2030.
- Competitive Landscape: 108 leading companies are profiled, covering market positioning, strategies, and recent developments.
Market Size (USD Mn)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Overview
Dercum’s Disease Market — Growth Trajectory
Dercum’s disease is a rare disorder that affects painful growths of fatty tissue called lipomas. Fat tissue is known as loose connective tissue, hence Dercum’s disease is a loose connective tissue disease. The lipomas mainly occur on the trunk, the upper arms, and upper legs and are found just below the skin but also can be found deeper in the body coupled to muscle, tendons, ligaments, or bone by connective tissue. Pain associated with Dercum’s disease can often be severe.
Dercum’s Disease Market — Growth Trajectory
Surgery
Liposuction
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Size Trend (USD Mn)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Dimensions
How this market is segmented
- By Treatment By Treatment is broken down into: Surgery, Medication, Liposuction, Electrotherapy, Acupuncture, Others.
- By End-user By End-user is broken down into: Hospital & Clinics, Ambulatory Surgical Centers, By End-user_Others.
- By Distribution Channel By Distribution Channel is broken down into: Hospital Pharmacies, Retail Pharmacies, By Distribution Channel_Others.
Geographic Analysis
Regional market breakdown
- North America North America market size reached $3.71B in 2018 and is projected to reach $6.84B by 2030, growing at a CAGR of 5.2%.
- Europe Europe market size reached $4.30B in 2018 and is projected to reach $7.66B by 2030, growing at a CAGR of 4.9%.
- Asia Pacific Asia Pacific market size reached $2.13B in 2018 and is projected to reach $4.18B by 2030, growing at a CAGR of 5.8%.
- Rest of the World Rest of the World market size reached $656.95M in 2018 and is projected to reach $1.27B by 2030, growing at a CAGR of 5.6%.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansResearch Methodology
Dercum’s Disease Market — How We Researched This Market
This report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.
Base Year
2021
Historical Period
2018 – 2021
Forecast Period
2021 – 2030
Primary Interviews
150+
Research Process
Historical data (2018–2021) and forecast period (2021–2030)
1
Problem Definition
- Market scoping
- Objective setting
- Framework design
2
Secondary Research
- Literature review
- Data mining
- Trend analysis
3
Primary Research
- Expert interviews
- Field visits
- Surveys
4
Data Analysis
- Quantitative modeling
- Statistical testing
- Validation
5
Insights & Reporting
- Synthesis
- Recommendations
- Visualization
Research Depth
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Historical vs. Forecast Data
Historical (observed)
Forecast (modelled)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansCompetitive Landscape & Porter's Five Forces
Dercum’s Disease Market — Competitive Analysis
Threat of New Entrants
The threat of new entrants in the global Dercum’s disease market is low. Any manufacturing company trying to enter the market is required to accept and abide by the mandatory regulatory standards set by the respective regulatory authorities of the country, such as the Food and Drug Administration (FDA), The Central Drugs Standard Control Organization (CDSCO), and others. Moreover, the market is also characterized by a reasonable degree of brand loyalty, where establishing a brand name is difficult for newcomers. Furthermore, the cost involved in the R&D of a product is comparatively high, which does not allow new players to enter the market easily.
Bargaining Power of Suppliers
The bargaining power of suppliers in the global Dercum’s disease market is moderate. The suppliers in the Dercum’s disease market are the developers and manufacturers of devices used for treating Dercum’s. The bargaining power of suppliers is a crucial factor in the global Dercum’s disease market and determines the strength of the industry. Many suppliers are currently present in the market due to the availability of a huge patient pool, high demand for Dercum’s treatment, and increasing government support. The existing key companies capture significant market share and monitor the costs of the devices. The switching cost of these suppliers is moderate because suppliers tend to enter long-term associations, partnerships, and deals with other manufacturing companies. The overall bargaining power of suppliers in the global Dercum’s disease market is hence moderate.
Threat of Substitutes
The threat of substitutes in the global Dercum’s disease market is low. Patients suffering from Dercum’s disease have surgical, medication, liposuction, electrotherapy, acupuncture treatment options that show promising results. Furthermore, many large- and medium-scale companies manufacture different types of devices and medications for Dercum’s treatment. Some small companies are providing their products at low prices to sustain themselves in this highly competitive market.
Bargaining Power of Buyers
The bargaining power of buyers is high in the global Dercum’s disease market. This is primarily due to the presence of a growing number of buyers in the industry. The market for Dercum’s disease is identified as having a significant customer base, considering the increasing number of rare diseases, and rising research and development activities. However, the buyers tend to use the products that have been provided by the top players irrespective of the pricing. Therefore, the bargaining power of buyers is high in the global Dercum’s disease market.
Intensity of Rivalry
The overall degree of competition in the global Dercum’s disease market is high. The number of competitors is high and offers a wide variety of products for Dercum’s disease. The reserved degree of product differentiation among existing players increases the intensity of rivalry in the market. The companies engaged in manufacturing drugs and treatments are developing advanced products for differentiating their brand from the competitors. Also, many prominent market players are entering into strategic partnerships, co-development activities, and tie-ups with established companies to overcome the competition.
Quantitative Analysis
Regional Breakdown
Regional market breakdown for Dercum’s Disease Market.
Regional Market Size (USD Mn)
Market estimates by geography (2030)
USD Mn
InsightEurope leads with $7.66B by 2030, while Asia Pacific is projected to grow fastest at a 5.8% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansRegional Market Data
| REGION | 2018 | 2021 | 2030 | CAGR | SHARE |
|---|---|---|---|---|---|
| North America | $3.71B | $4.52B | $6.84B | 5.2% | 34% |
| Europe | $4.30B | $5.25B | $7.66B | 4.9% | 38% |
| Asia Pacific | $2.13B | $2.60B | $4.18B | 5.8% | 21% |
| Rest of the World | $656.95M | $801.47M | $1.27B | 5.6% | 6% |
| Total | $10.80B | $13.18B | $19.96B | 5.2% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSegment Revenue (2030)
Surgery
Liposuction
Medication
Electrotherapy
Acupuncture
Others
01709341951286837
Segment Market Share
- Surgery31%
- Liposuction25%
- Medication21%
- Electrotherapy11%
- Acupuncture9%
- Others3%
Total Market Size
$19.96B
Market by Segment (2030)
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Surgery | $6.22B | 5.2% | 72% |
| Liposuction | $4.95B | 5.2% | 89% |
| Medication | $4.14B | 5.2% | 67% |
| Electrotherapy | $2.12B | 5.2% | 89% |
| Acupuncture | $1.85B | 5.2% | 89% |
| Others | $686.47M | 5.2% | 53% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansEmpower your Business
with InsightsSave over 20% on
with Insights
Save over 20% on
Annual Subscription
See plans for professionals or small and medium businesses.
Analytics
Dercum’s Disease Market — Key Findings
Analytical insights on Dercum’s Disease Market covering market dynamics, competitive landscape, and strategic outlook.
Key Analytical Findings
The Dercum’s Disease Market market is projected to reach $19.96B by 2030, growing at 5.2% CAGR. The Surgery segment holds the largest share.
Market Dynamics
Dercum’s disease is a combination of chronic painful adipose tissue. Treatment for this disease is centered on managing pain. Although there is no standard of care for managing pain, there are different pain management regimes that are promising. The key factors driving the global Dercum’s disease market growth include the rising prevalence of rare diseases and increasing research and development activities. Additionally, the rising number of strategic initiatives will provide growth opportunities for the market in the future. However, a lack of awareness among people about the disease might hamper the market's growth in the forecast period.
Market Drivers
The increasing prevalence of rare diseases is propelling the demand for effective treatment for Dercum’s disease. Rare diseases such as adiposis dolorosa, and lipomas along with the ongoing COVID-19 pandemic, account for a substantial burden globally. According to the NCBI survey, held in February 2021, approximately 2500 people per year with loose connective (adipose) tissue disease were seen, most patients with lipedema, six patients with FML-Type DD, and 10 patients with angiolipoma-type Dercum’s disease. Additionally, the same survey suggested that the prevalence of Dercum’s disease is 0.64% in the population, and the prevalence of lipedema in the USA is thought to be 11% in women though the range is 5 to 39%. A majority of people with Dercum’s disease are women.
Dercum's disease is characterized by multiple, painful growths of fatty tissue (lipomas). So, the number of patients suffering from rare diseases increasing globally. Moreover, the increasing cases of COVID-19 also have a significant impact on the growth of the Dercum’s disease market. Such rise in the number of diseases cases is anticipated to augment the demand for Dercum’s disease globally.
Market Opportunities
Dercum’s disease is a rare condition that is characterized by multiple, painful fatty tumors that occur chiefly in post-menopausal, obese women of middle age. It is also known as Adiposis Dolorosa, Anders' syndrome, and Dercum-Vitaut syndrome. Therefore, rise in the number of strategic initiatives in the form of mergers, acquisitions, product approval, collaborations, and partnerships to gain a competitive edge and offer advanced treatment options for Dercum’s disease. For instance, in August 2019, BioSpecifics Technologies Corporation, a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first-in-class collagenase-based product collagenase clostridium histolyticum, or CCH, marketed as XIAFLEX in the US and Xiapex in Europe.
Similarly, in August 2022, Caliway Biopharmaceutical Inc (CBI) announced that its first pipeline, CBL-514 has demonstrated promising clinical effectiveness and safety in reducing local fat through a mechanism of adipocyte apoptosis. Hence, such initiatives will help to propel the Dercum’s disease market.
Market Restraints
The lack of awareness regarding symptoms, ignorance, and not seeking timely diagnosis and treatment for Dercum’s disease is anticipated to hamper the market growth. The National Center for Biotechnology Information (NCBI) in February 2021, stated that less than 200,000 people globally suffer from Dercum’s disease. However, half of them could have been prevented by receiving proper treatment on time. The lack is awareness is more in the developing regions of the world where people are not conditioned to understand the therapeutic approach beyond the need.
According to the National Library of Medicine article published in December 2019, Dercum’s disease is more prevalent in women than in men, with increasing age, and in some ethnic groups. The study also stated that a significant proportion of the population suffering from Dercum’s did not receive proper treatment. As many got risk factors exist, including obesity, dietary factors, and comorbid conditions. Therefore, a lack of awareness regarding Dercum’s negatively impacts the growth of the Dercum’s disease market. However, several efforts are being undertaken by regulatory authorities in the form of campaigns and awareness programs to improve public awareness, which is expected to decrease the impact of restraints in the coming years.
Strategic Outlook and Future Directions
The novel coronavirus or the COVID-19 pandemic has negatively impacted the global Dercum’s disease industry since the rising number of decrum's disease cases have been affected since the healthcare service providers and frontline workers are focused more on handling the upcoming covid cases have reduced the significant consideration being paid to the decorum’s disease. Several countries have also implemented certain restrictions on imports and exports because of the pandemic. This has also affected the healthcare industry as many countries are dependent on other countries for raw material supply, component supply, system supply, and technology. This has also impacted the market as patients and staff need to work in proximity regularly. Furthermore, due to the closure of the operational facility, hospital and clinics were having a difficult time. Similarly, during the pandemic, 62% of healthcare professionals in the US had salary concerns. However, as the restrictions are lifted as COVID-19 cases decreases, treatment will be available in different parts of the world, and the trade restrictions are lifted, the supply chain should return to normalcy soon.
The emergence of coronavirus negatively impacted various sectors across the globe. The healthcare sector was also negatively impacted owing to production restrictions, cessation of clinical trials, and R&D activities. However, increasing number of techniques to confirm the presence or absence of coronavirus among patients is creating huge demand globally. The sudden surge in rare diseases has created a pressure among the market players to produce medication. In addition, the rising number of patients is driving the demand for decrum's disease treatment option. The commercialization of the products has also strengthened the market demand. Thus, these factors augmented the demand for decrum's disease treatment across worldwide.
The COVID-19 pandemic situation has resulted in many restrictions globally, still players of decrum's disease market were able to manage their product stock globally. Companies are trying to deal globally also finding out their way to deal with this pandemic situation. They are experiencing volatile demand flow, fluctuating by regions and market sectors. Hence, they are in regular contact with government authorities to maintain the product supply across the border. The outbreak of COVID-19 and the subsequent measures implemented by the government to contain it have badly affected the suppliers. Furthermore, Asia Pacific countries such as China, Japan, and India are also badly affected due to the pandemic. The demand-supply outlook is severely hampered by trade barriers. Government and private companies in the regions are also working together to issue advice for those undergoing treatment during these unprecedented times of COVID-19.
Market Value by Segment (2030)
Value (USD Mn)
Surgery
Liposuction
Medication
Electrotherapy
Acupuncture
Others
Companies
Key companies profiled in Dercum’s Disease Market
Profiles of 108 companies operating in the Dercum’s Disease Market market, including revenue, employee count, and market positioning where available.
Showing 108 of 108 companies
Novartis I
Novartis International AG
Healthcare
Company Headquarters: Basel, Switzerland Founded: 1966 Workforce: ~108,000 Company Working: Novartis International AG (Novartis) is engaged in the production of pharmaceutical drugs. It is a fully integrated life sciences company that provides research, product development, manufacturing, and distribution of products. It is an outstanding worldwide source of regenerative medicine technology, clinical research, education, and training for the constantly evolving healthcare industry. It ranks among the world’s top companies investing in research and development. It carries out research at Novartis locations and partner institutions worldwide: Cambridge, the US; Basel, Switzerland; East Hanover, US; Emeryville, US; and Shanghai, China. Sandoz, a Novartis division, is a global provider of generic pharmaceuticals and biosimilars.
Revenue$47.4B
Employees108,000
Market CapN/A
Founded1965
Basel, Switzerland
BHR Pharma
BHR Pharmaceuticals Ltd
Healthcare
Company Headquarters: England, UK Founded: 1990 Workforce: ~50 Company Working: BHR Pharmaceuticals Ltd is a fastest growing point of care diagnostic company which is involved in development medical devices. The company specialize in hematology, health equipment, immunology, point of care testing equipment, allergy testing supplies, migraine device, drug tests, and female health. Moreover, the company offers most technically advanced products and solutions to diagnose and treat as well as manage most prevalent diseases. The company has strong business presence in UK.
RevenueN/A
Employees50
Market CapN/A
Founded1989
England, UK
Raziel The
Raziel Therapeutics Ltd
Healthcare
Company Headquarters: Hamerkaz, Israel Founded: 2012 Workforce: ~10 Company Working: Raziel Therapeutics Ltd is a clinical-stage pharmaceutical company which is developing injectable therapeutics for the treatment of aesthetics and a variety of fat disorders. The company provide a single injection treatment into subcutaneous fat which is cause fast fat cell death at injection site as well as empowering medical professionals to enable patients with a better treatment fat reduction for long time periods without noninvasive procedure. The company has strong business presence in Israel.
RevenueN/A
Employees10
Market CapN/A
Founded2011
Hamerkaz, Israel
Caliway
Caliway
Healthcare
Company Headquarters: New Taipei City, Taiwan Founded: 2012 Workforce: <25 Company Working: Caliway is a clinical stage biopharmaceutical company which is involved in development of innovative therapeutics in the treatment of obesity and anti-aging disorders. The company developing small molecule for non-surgical fat reduction, Dercum’s disease, cellulite, lipoma, osteoarthritis, and others. Moreover, the company pipeline molecule CBL-514, is a first-in-class new drug which can activate adipocyte apoptosis at the injection site and efficiently reduce the subcutaneous fat without any serious side effects. The company has strong business presence in Taiwan.
RevenueN/A
Employees25
Market CapN/A
Founded2011
New Taipei City, Taiwan
Pfizer Inc
Pfizer Inc.
Food & Beverages
Company Headquarters: New York, US Founded: 1849 Workforce: ~83,000 Company Working: Pfizer Inc. (Pfizer) is a leading research-based biopharmaceutical company that applies science and resources to provide innovative treatments that extend and significantly improve lives. Pfizer discovers, develops, manufactures, and sells healthcare products worldwide. It operates through two segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs), and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, clinics, government agencies, and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. Furthermore, the company supplies its products in North America, South America, Asia-Pacific, Australia, Europe, Africa, and the Middle East.
Revenue$41.7B
Employees83,000
Market CapN/A
Founded1848
New York, US
Abbvie Inc
Abbvie Inc.
Healthcare
Company Overview Company Headquarters: Illinois, US Founded: 2013 Workforce: 30,000+ Company Working: Abbvie Inc. (Abbvie) is a pharmaceutical company that deals in various products addressing a variety of therapeutic areas such as oncology, immunology, neuroscience, virology, and general medicine. The company’s team consists of scientists, researchers, communicators, manufacturing specialists, and regulatory experts all across the globe. Abbvie targets specific difficult-to-cure diseases where it can leverage its core R&D expertise to advance science. It constantly works towards creating solutions that go beyond treating the illness to have a positive impact on patients’ lives and societies. The company comes up with new approaches towards addressing current health issues from life-threatening illness to chronic conditions.
Revenue$33.3B
Employees30,000
Market CapN/A
Founded2012
Illinois, US
Page 1 of 18
…
Go to page
Powering the world's best teams.
From next-gen startups to established enterprises.
What our clients say
Trusted by forward-thinking businesses
for data-driven intelligence
Noah Malgeri
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Michael Robert
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Joseph Aguayo
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Bong Lau
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Peter Groot Koerkamp
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Younghwan Choi
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Mark Irwin
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Rob Kooiker
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
Jason Lee
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Akif Moroglu
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Noah Malgeri
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Michael Robert
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Joseph Aguayo
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Bong Lau
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Peter Groot Koerkamp
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Younghwan Choi
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Mark Irwin
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Rob Kooiker
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
Jason Lee
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Akif Moroglu
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Dercum’s Disease Market
Starting from
$4,950